Dr. Paul Karpecki of Kentucky Eye Institute Joins Vial’s Anterior Scientific Advisory Board

San Francisco, CA. September 11, 2022 — Vial continues to expand its scientific advisory board with new member Dr. Paul Karpecki, who will act as a consultant to Vial’s Ophthalmology CRO. Dr. Karpecki is the Director of Corneal Services at Kentucky Eye Institute and Faculty Associate Professor at the University of Pikeville, Kentucky, College of Optometry.

Dr. Karpecki has over 20 years of experience as a thought leader and pioneer in optometry and over two decades of experience running some of the largest dedicated corneal health and dry eye research clinics in the U.S. He was selected as one of the top 25 dry eye experts worldwide to provide insights into dry eye within women at the Delphi International Society at Wilmer-Johns Hopkins.

“Dr. Karpecki is one of the most influential optometry physicians. His insights and contributions to Vial’s Ophthalmology CRO will lead to more efficient clinical trials with higher-quality results. Dr. Karpecki’s optometry expertise is unrivaled, and we are grateful he has joined our scientific advisory board,” said Simon Burns, Co-Founder and CEO of Vial.

Vial’s CRO Advisory Board has rapidly expanded and continues to pull in experts across therapeutic areas, including ophthalmology. Vial’s unique approach to leveraging experience from scientific advisors has helped them develop a deep insider’s view of the pain points of running clinical trials. Vial’s ophthalmology CRO distinguishes itself by utilizing digital technology, an extensive site network, an advisory board, and a proven enrollment playbook to streamline processes. Vial’s tech-enabled CRO provides novel clinical trial management services that deliver diverse enrollment, automated processes, and more accurate data for higher-quality trial results.

“I have a deep commitment to innovation which is why I find it rewarding to partner with startups eager for new and modern approaches. I enjoy collaborating with mission-driven companies like Vial to bring new technologies and treatments to the ophthalmic space,” said Dr. Karpecki on being an advisor to Vial’s ophthalmology CRO.

Dr. Karpecki is highly active in the clinical optometric community and is affiliated with the following organizations: The Dry Eye Summit for the profession, the CJO Optometric Dry Eye Guidelines for EyeCare, the DEWS II Diagnostic subcommittee, and the Tear Film and Ocular Surface Society Symposium.

He has also served as President of the Optometric Cataract, Cornea and Refractive Society, Chairman of the AOA Topical Interest Group in Refractive Surgery, Co-Chair of the Integrated Eyecare delivery task force for the American Society of Cataract and Refractive Surgeons, Chair of the American Optometric Association Continuing Education Committee, the AOA Congress Committee and Vice President of the Ocular Surface Society of Optometry.

About Vial: Vial is a tech-enabled, next-generation CRO that promises faster and higher-quality execution of trials. The Vial Contract Research Organization (CRO) delivers on the promise of faster trials through its innovative technology platform that powers trials end-to-end from site startup to database lock. The key to Vial’s tech-enabled platform is Vial’s modern, intuitive Electronic Source and powerful tooling for CRAs that enables considerable efficiencies. Vial operates across multiple Therapeutic Areas (Dermatology CROOphthalmology CROOncology CROGastroenterology CRO, and Neurology CRO). Vial is a San Francisco, California-based company with over 125 employees and has run over 750 trials from Phase I through Phase IV.